US Patent 8,653,137: Scope, Claims, and U.S. Patent Landscape
US Patent 8,653,137 is directed to a method of reducing bacterial infection occurrence in a human with pulmonary arterial hypertension (PAH) while the patient is undergoing PAH treatment. The method requires dilution of an active pharmaceutical ingredient (API) other than epoprostenol using a buffer comprising glycine at pH > 10, to produce a final solution that is then administered to the patient.
The claim set is built around three main technical pillars:
- Patient/clinical context: PAH patient undergoing PAH treatment, with bacterial infection risk reduction.
- Formulation constraints: glycine-based buffer, pH > 10 (with dependent ranges), and dilution of an API other than epoprostenol.
- Administration and outcome limitations: injection (including intravenous), with some claims limited to gram-negative growth reduction and specified formulation volumes/concentrations.
What do the independent and dependent claims cover (claim-by-claim scope)?
1. Claim 1 (core independent method)
Claim 1 covers:
- A method for reducing occurrence of a bacterial infection in a human suffering from PAH who is undergoing PAH treatment
- Where the reduction is associated with:
- Diluting a starting solution of an API other than epoprostenol
- With a buffer comprising glycine
- Buffer has pH > 10
- Final solution has pH > 10
- Final solution contains an amount of the API effective for treating PAH
- Then administering the final solution to the patient in need
Key scope levers embedded in Claim 1
- “API other than epoprostenol”: This is a categorical exclusion that helps narrow the method’s applicability to PAH drugs not classified as epoprostenol. Scope includes other PAH actives that can be used in PAH therapy.
- pH > 10 and glycine buffer: The combination is the formulation differentiator. It is not merely “basic pH” or “buffered solution.” The claim requires glycine and pH greater than 10 for both the buffer and final solution.
- Infection occurrence reduction: The method is an outcome-driven indication tied to infection risk reduction, not just a formulation.
2. Claim 2 (NaOH-explicit buffer)
Claim 2 limits Claim 1 to buffers where the buffer further comprises sodium hydroxide.
Scope effect: Narrows to glycine solutions adjusted with NaOH to reach high pH.
3. Claim 3 (pH window)
Claim 3 requires buffer pH between 10 and 12.
Scope effect: Narrows the broad pH > 10 limit to a defined interval.
4. Claim 4 (narrow pH window)
Claim 4 limits Claim 3 to pH between 10.2 and 10.8.
Scope effect: Tightens to a narrow high-pH band.
5. Claim 5 (final concentration broad band)
Claim 5 requires final solution concentration of the API between:
6. Claim 6 (final concentration narrower band)
Claim 6 requires final solution concentration between:
- 0.004 mg/mL to 0.13 mg/mL
7. Claim 7 (route)
Claim 7 requires the final solution is administered by injection.
8. Claim 8 (route narrower)
Claim 8 requires injection is intravenous injection.
9. Claim 9 (microbiology outcome)
Claim 9 limits the method to those where administration reduces growth of gram negative bacteria.
Scope effect: Adds a microbiological specificity. A high-level outcome like “reduces bacterial infection occurrence” may not inherently read on gram-negative growth unless the method is used and shown to reduce gram-negative bacterial growth.
10. Claim 10 (route repeat for claim 4 basis)
Claim 10 ties intravenous administration to the Claim 4 pH window by stating:
- where final solution is administered intravenously.
11. Claim 11 (specific buffer composition example)
Claim 11 specifies the buffer as a 50 mL solution comprising:
- 94 mg glycine
- 73.3 mg sodium chloride
- sodium hydroxide (amount implied to achieve required pH)
This claim is a concrete embodiment with fixed glycine and NaCl mass in a 50 mL buffer volume.
12. Claim 12 (injection)
Claim 12 ties Claim 11 to injection administration.
13. Claim 13 (intravenous injection)
Claim 13 ties Claim 12 to intravenous injection.
What is the technical and legal “center of mass” of the patent’s enforceable scope?
Formulation-dominant claim structure
The independent claim’s key limitations are formulation-driven:
- glycine-based buffer
- pH > 10
- final solution also pH > 10
- dilution of an API other than epoprostenol
- administration to reduce infection occurrence in PAH patients
This means potential infringement hinges on whether an accused method:
- Uses a glycine buffer, not merely any basic buffer.
- Maintains pH > 10 after dilution.
- Uses an API other than epoprostenol.
- Uses the formulation in a PAH patient undergoing PAH treatment with a method framed as infection reduction.
Route and concentration create “forks”
Dependent claims create additional potential claim layers:
- Intravenous-only pathway: Claims 7-8, 10, 13
- Concentration limits: Claims 5-6
- pH windows: Claims 3-4
- Specific buffer recipe: Claim 11
- Microbiology endpoint: Claim 9
This architecture allows the patent owner to pursue different infringement theories depending on how close a competitor’s formulation and use conditions align.
Scope map: what a competitor must do to fit (or avoid) the claims
A. “Glycine + pH > 10” is the main obstacle
To land inside Claim 1, the accused method must include a buffer comprising glycine that is adjusted to pH > 10, and the final diluted solution must also be pH > 10.
If a competitor substitutes:
- non-glycine buffers (e.g., phosphate/citrate/Tris)
- or glycine but uses final pH ≤ 10
then Claim 1 is harder to read onto the method.
B. “API other than epoprostenol” is an inclusion/exclusion gate
If the API is epoprostenol, the method is outside the literal “other than” limitation. But if the relevant PAH drug is not epoprostenol, Claim 1 is potentially implicated.
C. Outcome limitation: “reducing occurrence of bacterial infection”
Claim 1 ties the administration to reducing bacterial infection occurrence. For enforcement posture, this tends to function as:
- a method-of-use limitation, and
- a link between the formulation and infection reduction in the claimed population.
D. Gram-negative limitation narrows Claim 9
Even if a competitor overlaps formulation and patient population, Claim 9 requires reduction of gram-negative bacterial growth. That outcome tie is typically less likely to be met incidentally unless testing or operational use is aligned.
E. Concentration and route can separate infringement risk
Even when formulation and pH match, route and concentration-dependent claims can fall away:
- Non-injection routes avoid Claims 7-8, 12-13.
- IV administration is required for Claims 8, 10, 13.
- If the final API concentration falls outside Claim 5 or Claim 6 bands, those dependents drop, but Claim 1 can remain.
F. Exact buffer composition is a “last-mile” dependent constraint
Claim 11 is narrow because it fixes glycine and sodium chloride amounts in a 50 mL buffer solution with NaOH used to reach required pH. Competitors can design around Claim 11 while still potentially hitting Claim 1 or Claims 2-4.
Practical claim-by-claim “design-around” levers
The claim set creates multiple potential escape routes for a formulation competitor:
- Replace glycine buffer with a non-glycine buffer (if feasible while maintaining delivery stability).
- Keep buffer composition but set the final pH to 10 or below.
- Use the API as a PAH therapy but frame method such that it does not fall under the specific “reducing occurrence of bacterial infection” patient method-of-use.
- Avoid IV injection if only subcutaneous/oral routes apply (though PAH actives often constrain route).
- Stay outside concentration bands for Claims 5 and 6, while still maintaining enough to treat PAH (Claim 1 can still read if concentration remains within Claim 1 regardless of dependents).
Patent landscape implications: how this claim set positions around PAH formulations and infection risk
1. The patent sits at the intersection of PAH therapeutics and high-pH anti-infection formulation design
The high-level strategy is not “anti-bacterial drug.” It is formulation buffering (glycine, pH > 10) applied to a PAH API solution with the therapeutic use context aimed at reducing infection occurrence.
That positions the patent for coverage against:
- formulation processes that adjust pH using glycine-based high-pH buffering,
- dilution/administration workflows that maintain high pH in the final solution,
- PAH infusion center protocols that prepare “mixed” or diluted solutions before administration.
2. Likely claim targeting in litigation: formulation preparation and administration method
Given the method-of-use plus formulation and route limitations, the most actionable enforcement targets are:
- manufacturing or compounding steps that explicitly dilute PAH drugs into glycine-based high-pH final solutions, and
- administration protocols that keep the high-pH condition through IV injection into PAH patients.
3. The “API other than epoprostenol” language narrows scope but increases specificity
This wording suggests the inventor intentionally carved around epoprostenol-specific formulation regimes. That can matter in landscapes where multiple prostacyclin analogs exist (epoprostenol vs other agents). The patent’s enforceable reach depends on whether the competitor’s PAH active falls within “other than epoprostenol.”
What this patent likely does to competitor freedom to operate (FTO)
Competitor scenarios most likely to face risk
Risk is highest where all of the following align:
- PAH drug is used for PAH treatment
- clinical use includes infection occurrence reduction objectives
- compounding dilutes the API into a glycine buffer
- pH is greater than 10 in final solution
- administration is injection, especially IV
- and concentrations fall within claim bands if dependents are pursued
Competitor scenarios likely to reduce literal risk
- Switching from glycine to other buffer systems.
- Reducing pH to 10 or below at the final stage.
- Changing administration route away from injection/IV.
- Avoiding exact buffer recipe concentrations that match Claim 11.
- Using epoprostenol as the API (if that is the competitor’s active), which is excluded from Claim 1.
Key claim chart (condensed for investor and R&D review)
| Claim |
Core limitation(s) |
Main narrowing features |
| 1 |
Reduce bacterial infection occurrence in PAH patients undergoing PAH treatment; dilute an API other than epoprostenol with glycine buffer pH > 10; final solution pH > 10; administer |
No specific route, concentration, or exact pH window beyond >10 |
| 2 |
Same as 1 |
Buffer includes NaOH |
| 3 |
Same as 1 |
Buffer pH 10 to 12 |
| 4 |
Same as 1 |
Buffer pH 10.2 to 10.8 |
| 5 |
Same as 1 |
Final API concentration 0.001 to 1 mg/mL |
| 6 |
Same as 1 |
Final API concentration 0.004 to 0.13 mg/mL |
| 7 |
Same as 1 |
Administered by injection |
| 8 |
Same as 1 |
Injection is IV |
| 9 |
Same as 1 |
Administration reduces gram negative bacterial growth |
| 10 |
Same as 4 |
Intravenous administration tied to pH 10.2–10.8 |
| 11 |
Same as 1 |
Specific 50 mL buffer: 94 mg glycine, 73.3 mg NaCl, NaOH |
| 12 |
Same as 11 |
Administered by injection |
| 13 |
Same as 11 |
Administered by IV injection |
Key Takeaways
- US 8,653,137 claims a method-of-use for PAH patients that reduces bacterial infection occurrence via dilution of a non-epoprostenol PAH API into a glycine buffer at pH > 10, with the final solution maintained at pH > 10 and then administered.
- The enforceable scope is formulation-centric: glycine + pH > 10 in final solution is the primary gating limitation; route and concentration are layered via dependents.
- The claim set creates multiple infringement entry points (Claim 1 broad) and narrower “ladder rungs” (Claims 3-4 pH windows, Claims 5-6 concentration ranges, Claims 7-8 and 10/13 IV route, Claim 9 gram-negative growth, Claim 11 exact buffer composition).
- Design-arounds are structurally supported by the claim architecture: remove glycine, move final pH to 10 or below, change route away from IV injection, or use epoprostenol as the PAH API.
FAQs
1) Does US 8,653,137 cover all PAH drugs?
No. Claim 1 requires diluting an API other than epoprostenol.
2) Is pH > 10 required only for the buffer or also for the final solution?
Both. Claim 1 requires the buffer pH > 10 and the final solution pH > 10.
3) Are intravenous administrations required to infringe?
Not for Claim 1. IV is required for dependent claims 8, 10, and 13; injection is required for 7, 12, and 13.
4) What is the role of Claim 11?
Claim 11 fixes a specific buffer recipe (50 mL containing 94 mg glycine and 73.3 mg sodium chloride with NaOH), narrowing coverage to that composition.
5) What makes Claim 9 different from Claim 1?
Claim 9 adds a microbiology endpoint: the method reduces gram-negative bacterial growth, which is narrower than reducing infection occurrence generally.
References
1) US Patent 8,653,137, “Method for reducing bacterial infection in pulmonary arterial hypertension,” claim text as provided.
